FDA Approves New Ovarian Cancer Detection Drug by Purdue Researcher

The latest cancer detection discovery by Philip Low of Purdue University could change outcomes for ovarian cancer patients forever. He developed a new drug called Cytalux that binds a fluorescent marker to cancer cells. This illuminating compound is the first of its kind to be approved by the FDA, and it allows surgeons to find hidden tumors that may otherwise go undetected.

As the Purdue University Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, Dr. Low has made a significant impact in the world of cancer research. He believes that there is an opportunity to expand this new cancer detection technology into surgeries for all kinds of solid cancers. If surgeons can find additional malignant tissue by injecting an identifier that lights up the cancerous tumors, there might be room for a path forward in noninvasive robotic and endoscopic surgeries, too.

Learn more about this pioneering drug for ovarian cancer surgery and cancer detection.